UNSPSC 51162721: Mecysteine

This classification denotes a mucolytic agent with the molecular formula C4H9NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) RQ6L463N3B, chemically known as methyl cysteine, hydrochloride but more generally known as mecysteine, which bears US NIH Compound Identifier 4040. European Medicines Agency schedules Mecysteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08688MIG.

UNSPSC 51162721 Mecysteine is a Commodity code that in recent state and local solicitations encompasses pharmaceutical products and related healthcare delivery services to correctional and community health settings. The Washington State Department of Corrections' September 2026 RFQ for parenteral products, services, and equipment—including total parenteral nutrition solutions, intravenous solutions, and controlled substances for incarcerated individuals—represents the primary active opportunity under this code. State and local issuing bodies purchasing under this code include state correctional departments and county public health authorities. The scope of work involves sourcing and delivering specialized pharmaceutical products with stringent service requirements: parenteral nutrition bags must be delivered within 24 hours of order, other parenteral products within 8 hours, and vendors must demonstrate documented experience preparing IV solutions and adjusting nutrition preparations based on patient lab results.

The code shows recent activity in Washington State and Florida. The Washington State Department of Corrections' RFQQ RFQQK13020, due October 7, 2026, is soliciting parenteral products and services for eight correctional facilities across the state and anticipates awarding up to three contractors per region, with an initial contract term running through June 30, 2030 and fixed pricing required for the first two years. A separate June 2026 IFB from Seminole County, Florida (IFB60459723LAS) procured naloxone and drug deactivation systems, though this opportunity shows an anomalous response date of July 26, 2023, and does not clearly align with the mecysteine commodity classification. Washington State DOC's solicitation emphasizes small-business participation (25% goal), minority-owned (10%), women-owned (6%), and veteran-owned (5%) designations, with subcontractor inclusion requirements for disadvantaged businesses where economically prudent. Bidders must meet state business licensure and background-clearance requirements and maintain specified insurance including professional liability coverage.